Autor segons l'article: Arenas, M.; Algara, M.; De Febrer, G.; Rubio, C.; Sanz, X.; de la Casa, M. A.; Vasco, C.; Marin, J.; Fernandez-Leton, P.; Villar, J.; Torres-Royo, L.; Villares, P.; Membrive, I; Acosta, J.; Lopez-Cano, M.; Araguas, P.; Quera, J.; Rodriguez-Tomas, F.; Montero, A.;
Departament: Medicina i Cirurgia
Autor/s de la URV: Arenas Prat, Meritxell / Rodriguez Tomas, Elisabet
Paraules clau: X-ray computed tomography Very elderly Treatment outcome Tomography, x-ray computed Time Severity of illness index Sars-cov-2 Radiotherapy, conformal Radiotherapy dosage Radiotherapy Radiation response Prospective study Prospective studies Procedures Partial pressure Oxygen therapy Oxygen inhalation therapy Oxygen Multimodality cancer therapy Multicenter study Mortality Male Lung irradiation Lung diseases, interstitial Lung Low-dose radiation therapy Lactate dehydrogenase L-lactate dehydrogenase Interstitial lung disease Interleukin-6 Interleukin 6 Il6 protein, human Humans Human Hospital mortality Fibrin fragment d Fibrin fibrinogen degradation products Fibrin degradation product Ferritins Ferritin Female Diagnostic imaging Dexamethasone Covid-19 pneumonia Covid-19 Conformal radiotherapy Comorbidity Combined modality therapy Clinical trial Cause of death C-reactive protein C reactive protein Blood Antiinflammatory agent Anti-inflammatory effects Anti-inflammatory agents Aged, 80 and over Aged
Resum: Purpose To evaluate the efficacy and safety of lung low-dose radiation therapy (LD-RT) for pneumonia in patients with coronavirus disease 2019 (COVID-19). Materials and methods Inclusion criteria comprised patients with COVID-19-related moderate-severe pneumonia warranting hospitalization with supplemental O-2 and not candidates for admission to the intensive care unit because of comorbidities or general status. All patients received single lung dose of 0.5 Gy. Respiratory and systemic inflammatory parameters were evaluated before irradiation, at 24 h and 1 week after LD-RT. Primary endpoint was increased in the ratio of arterial oxygen partial pressure (PaO2) or the pulse oximetry saturation (SpO(2)) to fractional inspired oxygen (FiO(2)) ratio of at least 20% at 24 h with respect to the preirradiation value. Results Between June and November 2020, 36 patients with COVID-19 pneumonia and a mean age of 84 years were enrolled. Seventeen were women and 19 were men and all of them had comorbidities. All patients had bilateral pulmonary infiltrates on chest X-ray. All patients received dexamethasone treatment. Mean SpO(2) pretreatment value was 94.28% and the SpO(2)/FiO(2) ratio varied from 255 mm Hg to 283 mm Hg at 24 h and to 381 mm Hg at 1 week, respectively. In those who survived (23/36, 64%), a significant improvement was observed in the percentage of lung involvement in the CT scan at 1 week after LD-RT. No adverse effects related to radiation treatment have been reported. Conclusions LD-RT appears to be a feasible and safe option in a population with COVID-19 bilateral interstitial pneumonia in the presence of significant comorbidities.
Àrees temàtiques: Radiology, nuclear medicine and imaging Radiology, nuclear medicine & medical imaging Oncology General medicine
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: elisabet.rodriguezt@estudiants.urv.cat elisabet.rodriguezt@estudiants.urv.cat meritxell.arenas@urv.cat
Identificador de l'autor: 0000-0003-0815-2570
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Strahlentherapie Und Onkologie. 197 (11): 1010-1020
Referència de l'ítem segons les normes APA: Arenas, M.; Algara, M.; De Febrer, G.; Rubio, C.; Sanz, X.; de la Casa, M. A.; Vasco, C.; Marin, J.; Fernandez-Leton, P.; Villar, J.; Torres-Royo, L.; (2021). Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial). Strahlentherapie Und Onkologie, 197(11), 1010-1020. DOI: 10.1007/s00066-021-01803-3
DOI de l'article: 10.1007/s00066-021-01803-3
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV